Pharma firm enthused by deep access to China

China's commitment to foster innovation and advance high-standard opening-up has provided global pharmaceutical companies with broader access to its vast consumer base, enabling them to introduce innovative medical solutions to the world's second-largest healthcare market, said the top executive of a global pharmaceutical company.

"We see China as a source of innovation, and the country has made tremendous strides in creating an ecosystem that empowers innovators," said Jean-Christophe Tellier, CEO of UCB, a multinational biopharmaceutical company.

"We also need a market that welcomes innovation, and I feel there is a strong willingness in China to recognize innovation," Tellier said.